- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for breast cancer: past, present, and future
Authors
Keywords
Immunotherapy, Breast cancer, Review, Checkpoint inhibitor, Biomarkers, Clinical trials
Journal
CANCER AND METASTASIS REVIEWS
Volume 35, Issue 4, Pages 525-546
Publisher
Springer Nature
Online
2016-12-02
DOI
10.1007/s10555-016-9654-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract P2-11-09: A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data
- (2016) S-C Tang et al. CANCER RESEARCH
- Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
- (2016) S Adams et al. CANCER RESEARCH
- Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028
- (2016) HS Rugo et al. CANCER RESEARCH
- Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial
- (2016) LY Dirix et al. CANCER RESEARCH
- Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
- (2015) Rita Nanda et al. CANCER RESEARCH
- Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer
- (2015) Leisha A Emens et al. CANCER RESEARCH
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab
- (2015) Xiao Ni et al. OncoImmunology
- A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors
- (2015) Hatem H. Soliman et al. Oncotarget
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine
- (2014) TJ Vreeland et al. CANCER RESEARCH
- Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
- (2014) T. T. Junttila et al. CANCER RESEARCH
- Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
- (2014) Y. Saenger et al. CLINICAL CANCER RESEARCH
- Bispecific antibody platforms for cancer immunotherapy
- (2014) Roeland Lameris et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines
- (2014) Elham Mohit et al. Expert Review of Clinical Immunology
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies — Impact of effector cells
- (2014) Shan Chung et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab
- (2014) Michael A Postow et al. Journal of Translational Medicine
- Harnessing the immune system for the treatment of breast cancer
- (2014) Xinguo Jiang Journal of Zhejiang University-SCIENCE B
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Mitigating the toxic effects of anticancer immunotherapy
- (2014) Tara C. Gangadhar et al. Nature Reviews Clinical Oncology
- IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
- (2014) M. T. Isla Larrain et al. TUMOR BIOLOGY
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
- (2014) G. Chen et al. Cancer Immunology Research
- PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) H. Wimberly et al. Cancer Immunology Research
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity
- (2013) A. T. Vaughan et al. BLOOD
- Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
- (2013) Ursula Wiedermann et al. BREAST CANCER RESEARCH AND TREATMENT
- Myeloid-derived suppressor cells in breast cancer
- (2013) Joseph Markowitz et al. BREAST CANCER RESEARCH AND TREATMENT
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- The role of intratumoral and systemic IL-6 in breast cancer
- (2013) Christine Dethlefsen et al. BREAST CANCER RESEARCH AND TREATMENT
- Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
- (2013) Yan Ge et al. CANCER LETTERS
- Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
- (2013) Xiaoqiang Tang CANCER LETTERS
- Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
- (2013) Z. C. Hartman et al. CANCER RESEARCH
- Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer
- (2013) Yuan Huang et al. CURRENT DRUG TARGETS
- Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
- (2013) Baris Boyraz et al. CURRENT MEDICAL RESEARCH AND OPINION
- The role of tumor-associated macrophages in breast cancer progression
- (2013) ELIAS OBEID et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
- (2013) J. Yu et al. JOURNAL OF IMMUNOLOGY
- Interleukin-8 in Breast Cancer Progression
- (2013) Nataša Todorović-Raković et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer
- (2013) Michael S. Hwang et al. PLoS One
- Hydrazinocurcumin Encapsuled Nanoparticles “Re-Educate” Tumor-Associated Macrophages and Exhibit Anti-Tumor Effects on Breast Cancer Following STAT3 Suppression
- (2013) Xiwen Zhang et al. PLoS One
- Introducing the society for immunotherapy of cancer’s new journal: journal for immunoTherapy of cancer
- (2013) Pedro J Romero et al. Journal for ImmunoTherapy of Cancer
- Pertuzumab: new hope for patients with HER2-positive breast cancer
- (2012) M. Capelan et al. ANNALS OF ONCOLOGY
- Advances in bispecific biotherapeutics for the treatment of cancer
- (2012) Chad May et al. BIOCHEMICAL PHARMACOLOGY
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
- (2012) R Y Tsang et al. BRITISH JOURNAL OF CANCER
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Abstract 654: MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells
- (2012) Shinji K. Oyama et al. CANCER RESEARCH
- P1-13-01: An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence.
- (2012) DF Hale et al. CANCER RESEARCH
- Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
- (2012) I. Verbrugge et al. CANCER RESEARCH
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
- (2012) Leisha A Emens Expert Review of Anticancer Therapy
- A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
- (2012) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- The GP2 peptide: A HER2/neu-based breast cancer vaccine
- (2012) Kevin S. Clive et al. JOURNAL OF SURGICAL ONCOLOGY
- Therapeutic Cancer Vaccines: Current Status and Moving Forward
- (2012) J. Schlom JNCI-Journal of the National Cancer Institute
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
- (2012) Vivian L. Weiss et al. PLoS One
- Tumor Associated Macrophage × Cancer Cell Hybrids May Acquire Cancer Stem Cell Properties in Breast Cancer
- (2012) Jingxian Ding et al. PLoS One
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
- (2012) A. J. Rech et al. Science Translational Medicine
- Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway
- (2012) Jian Yang et al. STEM CELLS
- Differential macrophage programming in the tumor microenvironment
- (2012) Brian Ruffell et al. TRENDS IN IMMUNOLOGY
- Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer
- (2011) A. J. Montero et al. BREAST CANCER RESEARCH AND TREATMENT
- Dual HER2-targeted approaches in HER2-positive breast cancer
- (2011) Eugene R. Ahn et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients
- (2011) Elizabeth A. Mittendorf et al. CANCER
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- A Th1 cytokine–enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells
- (2011) Archana Thakur et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-Evoked Regulatory B Cells Promote Breast Cancer Metastasis by Converting Resting CD4+ T Cells to T-Regulatory Cells
- (2011) P. B. Olkhanud et al. CANCER RESEARCH
- Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
- (2011) J. Godin-Ethier et al. CLINICAL CANCER RESEARCH
- Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
- (2011) Scott K. Pruitt et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- AE37: a novel T-cell-eliciting vaccine for breast cancer
- (2011) Alan K Sears et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis
- (2011) Catherine E. Steding et al. IMMUNOLOGY
- Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions
- (2011) Damya Laoui et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures
- (2011) Yawei Yuan INTERNATIONAL JOURNAL OF ONCOLOGY
- Breast cancer stem cells, cytokine networks, and the tumor microenvironment
- (2011) Hasan Korkaya et al. JOURNAL OF CLINICAL INVESTIGATION
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating macrophages and clinical outcome in breast cancer
- (2011) S M A Mahmoud et al. JOURNAL OF CLINICAL PATHOLOGY
- Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells
- (2011) Jingyan Sun et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
- (2011) Sylvain Ladoire et al. JOURNAL OF PATHOLOGY
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
- (2011) Wenjin Yin et al. PLoS One
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted therapy in breast cancer: what's new?
- (2011) L Fang et al. SWISS MEDICAL WEEKLY
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome
- (2010) Michael J. Campbell et al. BREAST CANCER RESEARCH AND TREATMENT
- Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine
- (2010) Jarrod P. Holmes et al. CANCER
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- IDO inhibits T-cell function through suppressing Vav1 expression and activation
- (2010) Runmei Li et al. CANCER BIOLOGY & THERAPY
- Anti-HER2 vaccines: new prospects for breast cancer therapy
- (2010) Maha Zohra Ladjemi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antiestrogens Induce Transforming Growth Factor -Mediated Immunosuppression in Breast Cancer
- (2010) C. M. Joffroy et al. CANCER RESEARCH
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Cell Death Mechanisms Induced by Cytotoxic Lymphocytes
- (2010) L Chávez-Galán et al. Cellular & Molecular Immunology
- Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
- (2010) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
- (2010) Jeremy D. Gates et al. VACCINE
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
- (2009) Ursula Wiedermann et al. BREAST CANCER RESEARCH AND TREATMENT
- Arginase: an emerging key player in the mammalian immune system
- (2009) Markus Munder BRITISH JOURNAL OF PHARMACOLOGY
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients
- (2009) Mark G. Carmichael et al. CANCER
- The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
- (2009) M. Jager et al. CANCER RESEARCH
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
- (2009) M. Gobert et al. CANCER RESEARCH
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
- (2009) Emmanuelle Charafe-Jauffret et al. CANCER RESEARCH
- An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation
- (2009) Dimitrios Iliopoulos et al. CELL
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2009) L. C. Benavides et al. CLINICAL CANCER RESEARCH
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
- (2009) Leisha A. Emens et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
- (2009) Pravin T.P. Kaumaya et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
- (2009) Mary L. Disis et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
- (2009) J. Bostrom et al. SCIENCE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
- (2008) M K Robinson et al. BRITISH JOURNAL OF CANCER
- Optimal dose and schedule of an HER-2/neu(E75) peptide vaccine to prevent breast cancer recurrence
- (2008) Jarrod P. Holmes et al. CANCER
- Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells
- (2008) Johanna K. Morales et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
- (2008) C. Marcela Diaz-Montero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2008) G. E. Peoples et al. CLINICAL CANCER RESEARCH
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine
- (2008) Jarrod P. Holmes et al. JOURNAL OF CLINICAL ONCOLOGY
- Implications of the Cancer Stem-Cell Hypothesis for Breast Cancer Prevention and Therapy
- (2008) Madhuri Kakarala et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
- Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target
- (2008) Sandra D Bohling et al. MODERN PATHOLOGY
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Cancer Immunology
- (2008) Olivera J. Finn NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis
- (2007) Ping Zhang et al. MOLECULAR IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More